Provided by Tiger Fintech (Singapore) Pte. Ltd.

BiomX Inc.

0.6010
-0.0100-1.64%
Post-market: 0.5851-0.0159-2.65%18:03 EDT
Volume:37.14K
Turnover:22.38K
Market Cap:15.00M
PE:-0.18
High:0.6173
Open:0.6100
Low:0.5807
Close:0.6110
Loading ...

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
18 Apr

BiomX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

BiomX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 Apr

Biomx Announces Compliance With Nyse Guidelines on Audit Opinion Disclosure

THOMSON REUTERS
·
01 Apr

Biomx Inc. : H.c. Wainwright Raises Target Price to $21 From $2

THOMSON REUTERS
·
01 Apr

BRIEF-BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

Reuters
·
31 Mar

Biomx Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 for the Treatment of Diabetic Foot Osteomyelitis (Dfo)

THOMSON REUTERS
·
31 Mar

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

GlobeNewswire
·
31 Mar

BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026

Benzinga
·
25 Mar

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire
·
25 Mar

Biomx to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

THOMSON REUTERS
·
20 Mar

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

GlobeNewswire
·
20 Mar

Biomx Inc - Topline Results From Phase 2B Study Expected in Q1 2026

THOMSON REUTERS
·
26 Feb

Biomx Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

THOMSON REUTERS
·
26 Feb

Biomx Inc - Proceeds to Support Phase 2B Study of Bx004 for Cystic Fibrosis

THOMSON REUTERS
·
26 Feb

Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

Dow Jones
·
26 Feb

BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

BiomX regains compliance with NYSE American continued listing standards

TIPRANKS
·
16 Dec 2024

Biomx Inc. Receives Notice of Compliance With Nyse American Continued Listing Standards

THOMSON REUTERS
·
16 Dec 2024

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

GlobeNewswire
·
16 Dec 2024